1745. Project CLEAR (Changing Lives by Eradicating Antibiotic Resistance) randomized controlled trial (RCT): Serial decolonization of recently hospitalized methicillin-resistant Staphylococcus aureus (MRSA) carriers reduces risks of MRSA infections and all-cause infections in the 1-year post-hospitalization
Session: Oral Abstract Session: MRSA Prevention and Epidemiology
Saturday, October 29, 2016: 8:30 AM
Room: 288-290

Background:

Hospitalized MRSA carriers have an increased risk of infection that continues beyond hospital discharge. 60% of invasive MRSA disease occurs during this period. Serial decolonization following hospital discharge may provide protection.

Methods:

We conducted a RCT of hygienic education (E) vs. education plus serial topical decolonization (D) for recently discharged patients with a confirmed MRSA culture. Decolonization consisted of oral chlorhexidine (CHG) mouth wash, CHG bath/shower, and nasal mupirocin for 5 days twice a month for 6 months. Subjects were enrolled between Jan 2011-June 2014 and followed for one year. Primary outcome was time to MRSA infection defined by CDC criteria. Secondary outcomes included MRSA infection by clinical judgment, all infections by CDC criteria, and all infections by clinical judgment. Infection outcomes were based on blinded chart review of outpatient and inpatient visits by 2 infectious diseases physicians. We evaluated intention-to-treat and as-treated groups using proportional hazards models.

Results:

2,137 patients were enrolled (E = 1,069; D = 1,068). Total days in trial were D: 260,058 days (median 360.0) and E: 274,483 days (median 350.5). 6,033 unique medical records were reviewed. A significant reduction in MRSA infections and all-cause infections was seen (Table 1, Figure 1), with higher benefit seen in the D subset with full protocol adherence (51% of total D time) (Table 2). 28% of all MRSA infections involved bacteremia. Infections accrued at a stable rate across the one year follow up period. 40 adverse events deemed potentially related to study products were reported (CHG mouth wash (11), CHG soap (21), mupirocin (8)).

Conclusion:

In a RCT of over 2,000 patients, topical decolonization with mupirocin and CHG resulted in a 30% reduction in MRSA infection and a 16% reduction in all-cause infection in the one-year post-discharge period. For those (half) who were fully adherent to the 6 month protocol, reductions of 44% in MRSA infection and 40% in all-cause infection were seen.

Susan S. Huang, MD, MPH, FIDSA, FSHEA1, Raveena Singh, MA1, Samantha Eells, MPH2, Adrijana Gombosev, MS1, Steven Park, MD, PhD1, James a. Mckinnell, MD2, Daniel Gillen, PhD3, Diane Kim, BS1, Raul Macias-Gil, MD2, Syma Rashid, MD1, Michael Bolaris, MD2, Suzie S. Hong, MS1, Kaye Evans, BA4, Chenghua Cao, MPH1, Thomas Tjoa, MPH, MS1, Victor Quan, BA1, Gail Simpson, MD5, Ellena Peterson, PhD4, Mary K Hayden, MD6, Jennifer Lequieu, BS1, Eric Cui, BS1 and Loren Miller, MD, MPH7, (1)Division of Infectious Diseases and Health Policy Research Institute, University of California Irvine School of Medicine, Irvine, CA, (2)Infectious Disease Clinical Outcomes Research Unit, Division of Infectious Disease, Los Angeles Biomedical Research Institute at Harbor–University of California Los Angeles Medical Center, Torrance, CA, (3)Department of Statistics, University of California Irvine, Irvine, CA, (4)Department of Pathology and Laboratory Medicine, University of California Irvine School of Medicine, Orange, CA, (5)Ventura County Medical Center, Ventura, CA, (6)Division of Infectious Diseases, Rush University School of Medicine, Chicago, IL, (7)Infectious Disease Clinical Outcomes Research (ID-CORE), LA Biomed at Harbor-UCLA Medical Center, Torrance, CA

Disclosures:

S. S. Huang, Sage Products: Conducting studies in which participating healthcare facilities are receiving contributed product (no contribution in submitted abstract) , Participating healthcare facilities in my studies received contributed product
Molnlycke: Conducting studies in which participating healthcare facilities are receiving contributed product (no contribution in submitted abstract) , Participating healthcare facilities in my studies received contributed product
3M: Conducting studies in which participating healthcare facilities are receiving contributed product (no contribution in submitted abstract) , Participating healthcare facilities in my studies received contributed product
Clorox: Conducting studies in which participating healthcare facilities are receiving contributed product (no contribution in submitted abstract) , Participating healthcare facilities in my studies received contributed product

R. Singh, Sage Products: Conducting studies in healthcare facilities that are receiving contributed product , Conducting studies in healthcare facilities that are receiving contributed product
3M: Conducting studies in healthcare facilities that are receiving contributed product , Conducting studies in healthcare facilities that are receiving contributed product
Clorox: Conducting studies in healthcare facilities that are receiving contributed product , Conducting studies in healthcare facilities that are receiving contributed product

S. Eells, None

A. Gombosev, Sage Products: Conducting studies in healthcare facilities that are receiving contributed product , Conducting studies in healthcare facilities that are receiving contributed product
Molnlycke: Conducting studies in healthcare facilities that are receiving contributed product , Conducting studies in healthcare facilities that are receiving contributed product
3M: Conducting studies in healthcare facilities that are receiving contributed product , Conducting studies in healthcare facilities that are receiving contributed product
Clorox: Conducting studies in healthcare facilities that are receiving contributed product , Conducting studies in healthcare facilities that are receiving contributed product

S. Park, None

J. A. Mckinnell, Sage Products: Conducting studies in healthcare facilities that are receiving contributed product , Conducting studies in healthcare facilities that are receiving contributed product
3M: Conducting studies in healthcare facilities that are receiving contributed product , Conducting studies in healthcare facilities that are receiving contributed product
Clorox: Conducting studies in healthcare facilities that are receiving contributed product , Conducting studies in healthcare facilities that are receiving contributed product

D. Gillen, None

D. Kim, Sage Products: Conducting studies in healthcare facilities that are receiving contributed product , Conducting studies in healthcare facilities that are receiving contributed product
3M: Conducting studies in healthcare facilities that are receiving contributed product , Conducting studies in healthcare facilities that are receiving contributed product
Clorox: Conducting studies in healthcare facilities that are receiving contributed product , Conducting studies in healthcare facilities that are receiving contributed product

R. Macias-Gil, None

S. Rashid, Sage Products: Conducting studies in healthcare facilities that are receiving contributed product , Conducting studies in healthcare facilities that are receiving contributed product
Clorox: Conducting studies in healthcare facilities that are receiving contributed product , Conducting studies in healthcare facilities that are receiving contributed product

M. Bolaris, None

S. S. Hong, None

K. Evans, None

C. Cao, None

T. Tjoa, None

V. Quan, None

G. Simpson, None

E. Peterson, None

M. K. Hayden, Sage Products: Conducting studies in healthcare facilities that are receiving contributed product , Conducting studies in healthcare facilities that are receiving contributed product
Molnlycke: Conducting studies in healthcare facilities that are receiving contributed product , Conducting studies in healthcare facilities that are receiving contributed product

J. Lequieu, None

E. Cui, None

L. Miller, Sage Products: Conducting studies in healthcare facilities that are receiving contributed product , Conducting studies in healthcare facilities that are receiving contributed product
3M: Conducting studies in healthcare facilities that are receiving contributed product , Conducting studies in healthcare facilities that are receiving contributed product
Clorox: Conducting studies in healthcare facilities that are receiving contributed product , Conducting studies in healthcare facilities that are receiving contributed product

Previous Abstract | Next Abstract >>

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.